Table 4.
Efficacy outcomes for double combinations versus their own LABA by the end of triala
| Variables | IND/GLY | UMEC/VIL | ACLI/FOR | TIO/OLO |
|---|---|---|---|---|
| Lung function | ||||
| FEV1 5 minutes post morning dose (mL) | NSc | NAb | NSc | NSc |
| Peak FEV1 (mL) | 120 | 88–116 | 116–138 | 120 |
| Trough FEV1 (mL) | 70 | 90–95 | 45–81.5 | 85–92 |
| FEV1 AUC0–24 (mL) | 120 | NAb | NAb | 115 |
| Symptoms | ||||
| Dyspnea (TDI) | NSc | NSc | NS to 0.47 | 0.42 |
| TDI increase ≥1 point (%) | NSc | NAb | NSc | NAb |
| TDI increase ≥1 point (OR) | NAb | NSc | NSc | NAb |
| HRQL (SGRQ) | NSc | NSc | NSc | −1.693 |
| SGRQ increase ≥4 points (%) | NSc | NAb | NSc | 12.7 |
| SGRQ increase ≥4 points (OR) | NAb | NSc | NSc | NAb |
| Rescue medication (puffs/day) | −0.31 | NSc | NSc | −0.28 |
| Endurance test (seconds) | NAb | NAb | NAb | NS to 46.6 |
| Endurance SWT (seconds) | NAb | NAb | NAb | NAb |
| Exacerbations | ||||
| Number of all exacerbations (RR) | NAb | NAb | NSc | NAb |
| Time to first exacerbation all (HR) | NAb | NSc | NSc | NAb |
| Number of moderate-to-severe exacerbations (RR) | NAb | NAb | NSc | NAb |
| Time to first moderate-to-severe exacerbation (HR) | NAb | NAb | NSc | 0.83 |
Notes:
Data expressed as the minimum and maximum average value from all trials analyzed.
Outcomes with no information in any of the trials evaluated.
Outcomes with nonsignificant results in all available trials.
Abbreviations: ACLI/FOR, aclidinium/formoterol; AUC0–24, area under the curve from 0 to 24 hours post morning dose; FEV1, forced expiratory volume in the first second; HR, hazard ratio; HRQL, heath-related quality of life; IND/GLY, indacaterol/glycopyrronium; LABA, long-acting β2-agonist; NA, not available; NS, not significant; OR, odds ratio; RR, rate ratio; SGRQ, St George’s Respiratory Questionnaire; SWT, shuttle walking test; TDI, transitional dyspnea index; TIO/OLO, tiotropium/olodaterol; UMEC/VIL, umeclidinium/vilanterol.